Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Single-dose dexamethasone paclitaxel premedication

J P Micha1, M A Rettenmaier, R Dillman

  • 1Gynecologic Oncology Associates, Hoag Hospital Cancer Center, 351 Hospital Road, Suite 507, Newport Beach, California 92663, USA.

Gynecologic Oncology
|June 13, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Food retail environments around rural Victorian primary Schools: Associations with student diet and weight outcomes.

Health & place·2025
Same author

Repurposing CPAP machines as stripped-down ventilators.

Scientific reports·2021
Same author

Pesticide exposure and risk of systemic lupus erythematosus in an urban population of predominantly African-American women.

Lupus·2018
Same author

Care and After-Care of the Tuberculous.

The Indian medical gazette·2017
Same author

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.

Gynecologic oncology·2017
Same author

A very rare case of vaginal angiokeratoma.

European journal of gynaecological oncology·2014
Same journal

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026
Same journal

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.

Gynecologic oncology·2026
Same journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same journal

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same journal

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.

Gynecologic oncology·2026
Same journal

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
See all related articles

A standard premedication regimen significantly reduced hypersensitivity reactions (HSRs) in patients receiving paclitaxel chemotherapy. Patients who experienced HSRs could be safely retreated with paclitaxel after dose adjustment.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Paclitaxel is a vital chemotherapy agent for ovarian and gynecologic cancers.
  • Hypersensitivity reactions (HSRs) are a significant clinical challenge associated with paclitaxel administration.
  • Effective management strategies for paclitaxel-induced HSRs are crucial for patient safety and treatment continuity.

Purpose of the Study:

  • To evaluate the efficacy of a specific premedication regimen in mitigating paclitaxel-induced hypersensitivity reactions.
  • To assess the safety and feasibility of re-administering paclitaxel to patients who have previously experienced HSRs.

Main Methods:

  • A retrospective analysis of 183 consecutive patients treated with paclitaxel chemotherapy (1010 cycles).
  • Standard premedication included intravenous decadron, benadryl, and cimetidine prior to chemotherapy.

Related Experiment Videos

  • Investigation of treatment outcomes for patients experiencing HSRs, including those retreated with modified regimens.

    • Main Results:

    • A low incidence of hypersensitivity reactions (4 out of 1010 cycles) was observed with the standard premedication.
    • All patients who experienced HSRs recovered without complications.
    • Two patients successfully received multiple subsequent paclitaxel courses without recurrent reactions after additional oral decadron and standard premedication.

    Conclusions:

    • A single-dose intravenous decadron premedication regimen effectively decreases the incidence of paclitaxel-induced hypersensitivity reactions.
    • Patients experiencing paclitaxel HSRs can be safely retreated with paclitaxel, potentially with adjusted premedication protocols.
    • This approach enhances the tolerability and continued use of paclitaxel in gynecologic cancer treatment.